Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, and pharmacokinetics of ABT-354 in subjects with Alzheimer's disease on stable acetylcholinesterase inhibitors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ABT-354

Snippet

Sponsor: AbbVie | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED